Zentalis Pharmaceuticals, Inc. (ZNTL) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US98943L1070
Zentalis Pharmaceuticals, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 0.00 USD |
| Operating income | -152.81 m USD |
| EBIT | -136.62 m USD |
| Net income | -137.06 m USD |
| Diluted EPS – continuing operations | -1.91 USD |
Full history since 2017, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Zentalis Pharmaceuticals, Inc.
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is based in San Diego, California.
More stocks
- Crexendo, Inc. (CXDO)
- Seoul City Gas (017390.KS)
- QBeyond (QBY.DE)
- Dafeng TV Ltd (6184.TW)
- Humacyte, Inc. (HUMA)
- Sriracha Construction Public Company Limited (SRICHA.BK)
- VANJIA CORP (VNJA)
- Benfica (SLBEN.LS)
- Gs Global (001250.KS)
- Nitrasanata Dharma Tbk (JECX.JK)
- Sebang (004360.KS)
- LIGHTBRIDGE Corp (LTBR)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.